BrainsWay Ltd. BWAY
NasdaqGM
$11.92+0.46 (+4.01%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. With this update, there are now over 70 million covered lives in the U.S. with access to policies covering SWIFT. The announcement c
On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.
BWAY is in the latest 13F portfolio of 1 of the gurus we follow.
